Skip to main content
MitoCore Biosciences
← Back to Peptide Library

Adrenomedullin

Evidence: C

Cardiovascular / Vascular

2 min readLast reviewed August 25, 2026

Key facts

  • Research areaCardiovascular / Vascular
  • Study records55 human
  • Last updated2026-08-25

Evidence Snapshot

Evidence: CLimited Human Evidence
2026-08-25Last updated

Regulatory Context

This page summarizes research on the peptide and does not imply that the peptide is an FDA-approved drug or approved for a particular indication. Molecule-specific regulatory status requires verification against official regulatory records.

Research Takeaway

Adrenomedullin is a distinct mature human peptide and must not be merged with Adrenomedullin-2/Intermedin, CGRP, calcitonin, amylin, or proadrenomedullin-derived fragments.

Evidence boundary: Shared receptor-family or structural relationships do not establish molecular identity.

See all 6 evidence claims →

Quick Summary

Cardiovascular / Vascular

Adrenomedullin is an endogenous vasoactive peptide with a substantial direct-human infusion literature. Controlled studies demonstrate clear acute hemodynamic and neurohormonal activity, but the evidence base is much stronger for human pharmacology than for durable clinical efficacy.

Mechanism & Research Overview

Adrenomedullin is an endogenous vasoactive peptide with a substantial direct-human infusion literature. Controlled studies demonstrate clear acute hemodynamic and neurohormonal activity, but the evidence base is much stronger for human pharmacology than for durable clinical efficacy.

Evidence Claims

Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.

identity

Supported

Adrenomedullin is a distinct mature human peptide and must not be merged with Adrenomedullin-2/Intermedin, CGRP, calcitonin, amylin, or proadrenomedullin-derived fragments.

Does not establish

Evidence boundary: Shared receptor-family or structural relationships do not establish molecular identity.

Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers

human_evidence

Supported

Direct IV Adrenomedullin administration in controlled human studies produces measurable cardiovascular effects, including reductions in arterial pressure and increases in cardiac output or cardiac index.

Does not establish

Evidence boundary: These are primarily acute hemodynamic/pharmacology findings and do not establish long-term therapeutic efficacy.

Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers; Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension

human_evidence

Supported

Small human studies in heart failure and pulmonary hypertension reported acute hemodynamic and neurohormonal responses to Adrenomedullin infusion.

Does not establish

Evidence boundary: Small experimental cohorts and surrogate hemodynamic endpoints do not establish reduced mortality, hospitalization, or durable disease benefit.

Sources: Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension

Safety

Supported

A randomized phase 1 study evaluated the safety, tolerability, and pharmacokinetics of prolonged Adrenomedullin infusion in healthy men.

Does not establish

Evidence boundary: Phase 1 tolerability cannot define long-term or population-wide safety.

Sources: Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial

Evidence Boundary

Supported

Adrenomedullin's human evidence is stronger for direct pharmacology and hemodynamics than for durable therapeutic outcomes.

Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers; Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension; Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial

Regulatory Status

Supported

No molecule-specific regulatory conclusion is frozen for native Adrenomedullin in Stage 2A.

Safety & Evidence Limitations

Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.

  • Safety Consideration

    Hypotension and reflex/sympathetic cardiovascular responses are plausible from direct human hemodynamic studies.

  • Safety Consideration

    Acute infusion may increase heart rate and neurohormonal activation even when arterial pressure falls.

  • Safety Consideration

    Long-term safety and durable therapeutic benefit remain incompletely established by the frozen source set.

Research Areas Being Studied

Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.

Findings Reported in Studies

Educational summary only — reported in cited studies, not a claim of proven benefit.

Show findings from 5 human studies
  • Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial (2020):
  • Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension (2000):
  • Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers (2000):
  • Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure (2000):
  • Adrenomedullin: a hypotensive hormone in man (1997):

Study Tables by Evidence Type

5 study records

Human Studies & Clinical Data(5)

Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial

2020

PMID 32021087 · DOI 10.2147/DDDT.S225220

Population / Model
Healthy males; randomized double-blind phase 1; placebo and multiple IV infusion rates
Dose / Duration / Finding

Evaluated 12-hour Adrenomedullin infusion pharmacodynamics, tolerability, and safety across multiple dose groups.

DOIPubMed

Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension

2000

PMID 11083748

Population / Model
13 patients with precapillary pulmonary hypertension
Dose / Duration / Finding

Infusion increased cardiac index and reduced pulmonary vascular resistance/systemic pressure; aldosterone decreased.

PubMed

Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers

2000

PMID 10720032 · DOI 10.1210/jcem.85.3.6422

Population / Model
Eight healthy volunteers; randomized placebo-controlled crossover
Dose / Duration / Finding

Acute infusion increased cardiac output and heart rate, lowered diastolic pressure, stimulated renin/norepinephrine/prolactin, and did not significantly increase natriuresis.

DOIPubMed

Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure

2000

PMID 10662746

Population / Model
Seven CHF patients and seven healthy subjects, with placebo controls
Dose / Duration / Finding

Acute infusion increased cardiac index, reduced filling pressure and arterial pressure, and increased urine/sodium excretion; aldosterone fell in CHF patients.

PubMed

Adrenomedullin: a hypotensive hormone in man

1997

PMID 9176019

Population / Model
Eight healthy male subjects; placebo-controlled randomized study
Dose / Duration / Finding

IV human Adrenomedullin reduced arterial pressure at studied doses; renal/electrolyte effects were limited under the protocol.

PubMed

Animal / Cell / Preclinical Data

No Animal / Cell / Preclinical Data Listed Yet

This section will be updated as sources are added.

Regulatory Documents & Official Trial Registries

No Regulatory Documents & Official Trial Registries Listed Yet

This section will be updated as sources are added.

Anecdotal Reported Patterns — Not Medical Advice

Anecdotal Reported Patterns — Not Medical Advice

Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.

Lab Markers to Discuss With a Clinician

Educational topics only — not self-monitoring instructions.

FAQ

Controlled human infusion studies show that Adrenomedullin can produce measurable cardiovascular and neurohormonal effects, including vasodilation, lower arterial pressure, and changes in cardiac output or cardiac index. These studies establish direct human pharmacology, but most are small and short-term.

Disclaimer

Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.

Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.

Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.

Content status: Published. Last updated 2026-08-25.

Follow research updates for Adrenomedullin

Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.

Sign in to follow research updates for Adrenomedullin

Get updates when new studies or safety notes are added for this peptide.

Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.

Interests (optional)